Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders Pub Date : 2024-08-28 DOI:10.1016/j.parkreldis.2024.107115

Avner Thaler , Saar Anis , Penina Ponger , Tsviya Fay-Karmon , Vered Livneh , Achinoam Faust-Socher , Lior Greenbaum , Johnathan Reiner , Ariela Hilel , Hertzel Shabtai , Roy N. Alcalay , Ruth Djaldetti , Sharon Hassin-Baer , Adi Ezra , Anat Mirelman , Nir Giladi , Tanya Gurevich

{"title":"Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations","authors":"Avner Thaler , Saar Anis , Penina Ponger , Tsviya Fay-Karmon , Vered Livneh , Achinoam Faust-Socher , Lior Greenbaum , Johnathan Reiner , Ariela Hilel , Hertzel Shabtai , Roy N. Alcalay , Ruth Djaldetti , Sharon Hassin-Baer , Adi Ezra , Anat Mirelman , Nir Giladi , Tanya Gurevich","doi":"10.1016/j.parkreldis.2024.107115","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG).</p></div><div><h3>Objective</h3><p>To compare descriptive data of LCIG treatment in <em>GBA1-</em>PD and <em>LRRK2-</em>PD.</p></div><div><h3>Methods</h3><p>This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status.</p></div><div><h3>Results</h3><p>Fifty-two iPD, 15 <em>LRRK2</em>-PD and 23 <em>GBA1</em>-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. <em>GBA1</em>-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with <em>LRRK2</em>-PD and iPD. <em>LRRK2</em>-PD and iPD had significantly longer duration of LCIG treatment compared with <em>GBA1</em>-PD (p < 0.01).</p></div><div><h3>Conclusion</h3><p>Overall, LCIG treatment was well tolerated in <em>LRRK2</em>-PD and <em>GBA1</em>-PD. <em>GBA1</em>-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"127 ","pages":"Article 107115"},"PeriodicalIF":3.1000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinsonism & related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1353802024011271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG).

Objective

To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD.

Methods

This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status.

Results

Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01).

Conclusion

Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

查看原文本刊更多论文

左旋多巴-卡比多巴肠道凝胶治疗晚期帕金森病：LRRK2和GBA1突变的影响

背景晚期帕金森病（PD）可以用左旋多巴-卡比多巴肠溶胶（LCIG）治疗。方法这项多中心回顾性研究比较了从接受 LCIG 治疗的帕金森病患者电子病历中获得的临床数据。结果本研究共纳入52例iPD、15例LRRK2-PD和23例GBA1-PD患者。未发现 LCIG 每日剂量或左旋多巴等效每日剂量存在差异。与 LRRK2-PD 和 iPD 相比，GBA1-PD 在开始使用 LCIG 时的病程明显更短（p = 0.01），出现幻觉的次数更多（p = 0.03）。与 GBA1-PD 相比，LRRK2-PD 和 iPD 的 LCIG 治疗持续时间明显更长（p = 0.01）。GBA1-PD在病程中需要LCIG的时间更早，治疗期间出现幻觉的频率更高，这证明他们的病程更严重。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parkinsonism & related disorders 医学-临床神经学

CiteScore

6.20

自引率

4.90%

发文量

292

审稿时长

39 days

期刊介绍： Parkinsonism & Related Disorders publishes the results of basic and clinical research contributing to the understanding, diagnosis and treatment of all neurodegenerative syndromes in which Parkinsonism, Essential Tremor or related movement disorders may be a feature. Regular features will include: Review Articles, Point of View articles, Full-length Articles, Short Communications, Case Reports and Letter to the Editor.